Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/99940
Title: | EURO-WABB: an EU rare diseases registry for Wolfram syndrome, Alström syndrome and Bardet-Biedl syndrome |
Author: | Farmer, Amy Aymé, Ségolène López de Heredia, Miguel Maffei, Pietro McCafferty, Susan Młynarski, Wojciech Nunes Martínez, Virginia Parkinson, Kay Paquis-Flucklinger, Véronique Rohayem, Julia Sinnott, Richard Tillmann, Vallo Tranebjærg, Lisbeth Barrett, Timothy G. |
Keywords: | Malalties rares Diabetis Estadística mèdica Monitoratge de pacients Bases de dades web Europa Rare diseases Diabetes Medical statistics Patient monitoring Web databases Europe |
Issue Date: | 27-Aug-2013 |
Publisher: | BioMed Central |
Abstract: | Background: Wolfram, Alström and Bardet-Biedl (WABB) syndromes are rare diseases with overlapping features of multiple sensory and metabolic impairments, including diabetes mellitus, which have caused diagnostic confusion. There are as yet no specific treatments available, little or no access to well characterized cohorts of patients, and limited information on the natural history of the diseases. We aim to establish a Europe-wide registry for these diseases to inform patient care and research. Methods: EURO-WABB is an international multicenter large-scale observational study capturing longitudinal clinical and outcome data for patients with WABB diagnoses. Three hundred participants will be recruited over 3 years from different sites throughout Europe. Comprehensive clinical, genetic and patient experience data will be collated into an anonymized disease registry. Data collection will be web-based, and forms part of the project's Virtual Research and Information Environment (VRIE). Participants who haven't undergone genetic diagnostic testing for their condition will be able to do so via the project. Conclusions: the registry data will be used to increase the understanding of the natural history of WABB diseases, to serve as an evidence base for clinical management, and to aid the identification of opportunities for intervention to stop or delay the progress of the disease. The detailed clinical characterisation will allow inclusion of patients into studies of novel treatment interventions, including targeted interventions in small scale open label studies; and enrolment into multi-national clinical trials. The registry will also support wider access to genetic testing, and encourage international collaborations for patient benefit. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1186/1471-2431-13-130 |
It is part of: | BMC Pediatrics, 2013, vol. 13, p. 130 |
URI: | http://hdl.handle.net/2445/99940 |
Related resource: | http://dx.doi.org/10.1186/1471-2431-13-130 |
ISSN: | 1471-2431 |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
636263.pdf | 830.48 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License